Neuromodulation Focused Company Axonics Gets 28% Price Target Bump By This Analyst On Solid Q2 Performance
[ad_1] Axonics Inc AXNX reported a 50% Y/Y increase in Q2 sales to $69 million, beating the consensus of $59 million. Sacral neuromodulation (SNM) revenue was $55.8 million, and Bulkamid…